Suppr超能文献

随机比较三种姑息治疗方案,包括近距离放射治疗、光动力疗法和 APC 在恶性吞咽困难患者中的应用(CONSORT 1a)(修订版 II)。

Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II).

机构信息

Gastroenterology Department, Medical Center for Postgraduate Education and Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.

出版信息

Am J Gastroenterol. 2011 Sep;106(9):1612-20. doi: 10.1038/ajg.2011.178. Epub 2011 Jun 14.

Abstract

OBJECTIVES

Because most esophageal cancers are diagnosed at an advanced stage, a majority of patients require palliative dysphagia treatment. Dysphagia severity and the need for repeated re-canalization procedures significantly affect patients' quality of life (QoL). The aim of this study was to establish whether combining argon plasma coagulation (APC) of the neoplastic esophageal tissue with another re-canalization method results in a longer dysphagia-free period compared with APC alone.

METHODS

We conducted a randomized trial in 93 patients with malignant dysphagia. Patients were followed until death. We compared three regimens of esophageal re-canalization; APC combined with high dose rate (HDR) brachytherapy, APC combined with photodynamic therapy (PDT), and APC alone. The primary outcome measure was the dysphagia-free period following randomization. Secondary measures were survival, QoL, treatment-associated complications, and treatment tolerance. A per-protocol analysis was carried out.

RESULTS

The time to first dysphagia recurrence was significantly different between each combination treatment group and the control group (overall test: P=0.006; HDR vs. control, log-rank P=0.002, PDT vs. control, log-rank P=0.036), but not different between the combination groups (HDR vs. PDT, log-rank P=0.36). The median time to first dysphagia recurrence was 88, 59, and 35 days in the HDR, PDT, and control groups, respectively. There was no difference in overall survival between the study groups (P=0.27). No deaths, perforations, hemorrhages, or fistula formations were attributed to treatment. The only major complication was fever, occurring in three PDT patients. Minor complications were observed significantly more often in the combination treatment groups and included pain in both groups, transient dysphagia worsening, and skin sensitivity in the PDT group. The QoL 30 days after treatment in the HDR group was significantly better than in the other groups.

CONCLUSIONS

In patients with inoperable esophageal cancer, palliative combination treatment of dysphagia with APC and HDR or PDT was significantly more efficient than APC alone, and was safe and well tolerated. APC combined with HDR resulted in fewer complications and better QoL than APC with PDT or APC alone (CONSORT 1b).

摘要

目的

由于大多数食管癌在晚期才被诊断出来,因此大多数患者需要姑息性吞咽困难治疗。吞咽困难的严重程度和反复再通治疗的需求会显著影响患者的生活质量(QoL)。本研究旨在确定与单独使用氩等离子体凝固(APC)相比,将肿瘤性食管组织的 APC 与另一种再通方法结合是否能延长无吞咽困难期。

方法

我们对 93 例恶性吞咽困难患者进行了随机试验。患者一直随访至死亡。我们比较了三种食管再通方案;APC 联合高剂量率(HDR)近距离放射治疗、APC 联合光动力疗法(PDT)和 APC 单独治疗。主要观察指标是随机分组后无吞咽困难期。次要观察指标为生存、QoL、治疗相关并发症和治疗耐受性。进行了意向治疗分析。

结果

各组与对照组相比,每种联合治疗组与对照组的首次吞咽困难复发时间均有显著差异(总体检验:P=0.006;HDR 与对照组,对数秩检验 P=0.002,PDT 与对照组,对数秩检验 P=0.036),但联合治疗组之间无差异(HDR 与 PDT,对数秩检验 P=0.36)。HDR、PDT 和对照组的首次吞咽困难复发时间中位数分别为 88、59 和 35 天。各组之间的总生存率无差异(P=0.27)。无死亡、穿孔、出血或瘘形成与治疗有关。唯一的主要并发症是发热,发生在 3 例 PDT 患者中。联合治疗组观察到的次要并发症明显更多,包括两组均有疼痛、短暂吞咽困难恶化和 PDT 组皮肤敏感性。HDR 组治疗后 30 天的 QoL 明显优于其他组。

结论

对于无法手术的食管癌患者,姑息性联合治疗吞咽困难的 APC 联合 HDR 或 PDT 比单独 APC 更有效,并且安全且耐受性良好。与单独使用 APC 联合 PDT 或单独使用 APC 相比,APC 联合 HDR 导致的并发症更少,QoL 更好(CONSORT 1b)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验